These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. p-mTOR, p-ERK and PTEN Expression in Tumor Biopsies and Organoids as Predictive Biomarkers for Patients with HPV Negative Head and Neck Cancer. de Kort WWB; de Ruiter EJ; Haakma WE; Driehuis E; Devriese LA; van Es RJJ; Willems SM Head Neck Pathol; 2023 Sep; 17(3):697-707. PubMed ID: 37486536 [TBL] [Abstract][Full Text] [Related]
6. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. Weidhaas JB; Harris J; Schaue D; Chen AM; Chin R; Axelrod R; El-Naggar AK; Singh AK; Galloway TJ; Raben D; Wang D; Matthiesen C; Avizonis VN; Manon RR; Yumen O; Nguyen-Tan PF; Trotti A; Skinner H; Zhang Q; Ferris RL; Sidransky D; Chung CH JAMA Oncol; 2017 Apr; 3(4):483-491. PubMed ID: 28006059 [TBL] [Abstract][Full Text] [Related]
7. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer. Beckham TH; Barney C; Healy E; Wolfe AR; Branstetter A; Yaney A; Riaz N; McBride SM; Tsai CJ; Kang J; Yu Y; Chen L; Sherman E; Dunn L; Pfister DG; Tan J; Rupert R; Bonomi M; Zhang Z; Lobaugh SM; Grecula JC; Mitchell DL; Wobb JL; Miller ED; Blakaj DM; Diavolitsis VM; Lee N; Bhatt AD Int J Cancer; 2020 Jul; 147(1):107-115. PubMed ID: 31609479 [TBL] [Abstract][Full Text] [Related]
8. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Linge A; Lohaus F; Löck S; Nowak A; Gudziol V; Valentini C; von Neubeck C; Jütz M; Tinhofer I; Budach V; Sak A; Stuschke M; Balermpas P; Rödel C; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Buchholz F; Aust DE; Baretton GB; Thames HD; Dubrovska A; Alsner J; Overgaard J; Krause M; Baumann M; Radiother Oncol; 2016 Dec; 121(3):364-373. PubMed ID: 27913065 [TBL] [Abstract][Full Text] [Related]
9. Concurrent radiotherapy plus epidermal growth factor receptor inhibitors in patients with human papillomavirus-related head and neck cancer. Pajares B; Perez-Villa L; Trigo JM; Toledo MD; Alvarez M; Jimenez B; Medina JA; de Luque V; Jerez JM; Alba E Clin Transl Oncol; 2014 Apr; 16(4):418-24. PubMed ID: 24193865 [TBL] [Abstract][Full Text] [Related]
10. Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis. Tang WH; Sun W; Long GX Medicine (Baltimore); 2020 Sep; 99(36):e21785. PubMed ID: 32899005 [TBL] [Abstract][Full Text] [Related]
11. Assessment of cancer stem cell marker expression in primary head and neck squamous cell carcinoma shows prognostic value for aldehyde dehydrogenase (ALDH1A1). Szafarowski T; Sierdziński J; Ludwig N; Głuszko A; Filipowska A; Szczepański MJ Eur J Pharmacol; 2020 Jan; 867():172837. PubMed ID: 31811857 [TBL] [Abstract][Full Text] [Related]
12. nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma. Johnson KCC; Ley J; Oppelt P; Lu J; Gay HA; Daly M; Jackson R; Rich J; Pipkorn P; Paniello RC; Zevallos J; Thorstad W; Adkins DR Med Oncol; 2019 Oct; 36(11):93. PubMed ID: 31595355 [TBL] [Abstract][Full Text] [Related]
13. Combined CD44, c-MET, and EGFR expression in p16-positive and p16-negative head and neck squamous cell carcinomas. Baschnagel AM; Tonlaar N; Eskandari M; Kumar T; Williams L; Hanna A; Pruetz BL; Wilson GD J Oral Pathol Med; 2017 Mar; 46(3):208-213. PubMed ID: 27442811 [TBL] [Abstract][Full Text] [Related]
14. Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer. de Roest RH; van der Heijden M; Wesseling FWR; de Ruiter EJ; Heymans MW; Terhaard C; Vergeer MR; Buter J; Devriese LA; de Boer JP; Navran A; Hoeben A; Vens C; van den Brekel M; Brakenhoff RH; Leemans CR; Hoebers F Radiother Oncol; 2022 Oct; 175():112-121. PubMed ID: 35973619 [TBL] [Abstract][Full Text] [Related]
15. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. Bauman JE; Austin MC; Schmidt R; Kurland BF; Vaezi A; Hayes DN; Mendez E; Parvathaneni U; Chai X; Sampath S; Martins RG Br J Cancer; 2013 Oct; 109(8):2096-105. PubMed ID: 24064970 [TBL] [Abstract][Full Text] [Related]
16. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504 [TBL] [Abstract][Full Text] [Related]
17. Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. Patil S; Linge A; Grosser M; Lohaus F; Gudziol V; Kemper M; Nowak A; Haim D; Tinhofer I; Budach V; Guberina M; Stuschke M; Balermpas P; Rödel C; Schäfer H; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Boeke S; Zips D; Baretton GB; Baumann M; Krause M; Löck S; Radiother Oncol; 2022 Jun; 171():91-100. PubMed ID: 35429503 [TBL] [Abstract][Full Text] [Related]
18. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study. Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651 [TBL] [Abstract][Full Text] [Related]
19. Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas. Levy A; Blanchard P; Bellefqih S; Brahimi N; Guigay J; Janot F; Temam S; Bourhis J; Deutsch E; Daly-Schveitzer N; Tao Y Strahlenther Onkol; 2014 Sep; 190(9):823-31. PubMed ID: 24638267 [TBL] [Abstract][Full Text] [Related]
20. Preclinical trial comparing radiotherapy alone versus standard radiochemotherapy in three human papilloma virus (HPV) negative and three HPV-positive head and neck squamous cell carcinoma (HNSCC) xenograft tumour models. Valentini C; Ebert N; Koi L; Pfeifer M; Löck S; Erdmann C; Krause M; Baumann M Radiother Oncol; 2023 Jun; 183():109546. PubMed ID: 36813172 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]